Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7884263 | 0.99 | KMT2A (0.41) | KMT2AMEN1RXFP1SCN9AFLT3 | |
| SCHEMBL7877857 | 0.86 | MEN1 (0.47) | KMT2AMEN1RXFP1FLT3NPC1 | |
| SCHEMBL7880873 | 0.85 | RXFP1 (0.43) | KMT2AMEN1RXFP1FLT3NPC1 | |
| SCHEMBL7884286 | 0.85 | MEN1 (0.38) | KMT2AMEN1SCN9ADRD2DRD3 | |
| SCHEMBL7881957 | 0.85 | MEN1 (0.48) | KMT2AMEN1RXFP1FLT3PDGFRB | |
| SCHEMBL7881140 | 0.85 | RXFP1 (0.45) | KMT2AMEN1RXFP1FLT3 | |
| SCHEMBL7879705 | 0.85 | MEN1 (0.40) | KMT2AMEN1SCN9A | |
| SCHEMBL7879877 | 0.85 | FLT3 (0.42) | KMT2AMEN1RXFP1FLT3NPC1 | |
| SCHEMBL7881076 | 0.84 | RXFP1 (0.44) | KMT2AMEN1RXFP1FLT3 | |
| SCHEMBL7877961 | 0.84 | MEN1 (0.41) | KMT2AMEN1SCN9ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |